Aurora Cannabis Inc. (ACB) Income Statement

The trajectory from mid-2025 through early 2027 shows a rapid shift from mid-teens growth to severe contraction within approximately three quarters, with the $94.2M peak in 2026Q3 appearing anomalous rather than a sustainable run-rate. The collapse to $38.1M in 2026Q4 followed by a partial rebound to $67.6M suggests significant business disruption—potentially restructuring, product line exits, or loss of key distribution channels. Investors should assess whether the 2027Q1 stabilization represents a genuine floor or merely a temporary pause in a broader revenue erosion trajectory.

The repeated appearance of 89.6% gross margins (2026Q1 and 2025Q3) with identical $9.2M COGS on similar revenue levels raises substantive questions about the accounting treatment applied in those periods, as such margins are virtually unheard of in cannabis manufacturing. The subsequent degradation to 35.7% in 2026Q2, then to negative territory by 2027Q1, suggests either non-recurring credits reversing or genuine unit economics deteriorating under pressure. Peer margins clustering in the 3.7% to 41.4% range further underscore that ACB's historical margin peaks appear disconnected from sector-normal operational economics.

The relative stability of SG&A across all ten quarters suggests a fixed cost structure that management has been unable or unwilling to scale in proportion to revenue contraction. With SG&A consuming 60.5% of revenue in 2027Q1 versus 43.3% in 2026Q3, the operating cost base appears fundamentally misaligned with current revenue levels. For the business to return to breakeven at the 2027Q1 revenue run-rate, SG&A would need to be reduced by roughly half—a magnitude of restructuring not yet evident in the reported expense lines.